The article from the World Health Organization (WHO) titled “WHO adds an HPV vaccine for single-dose use” highlights important advancements in the global initiative to combat cervical cancer through HPV vaccination, specifically through the introduction of a new single-dose HPV vaccine (SD-HPV Vac). This milestone aims to transform how girls are vaccinated against cervical cancer, particularly in regions with limited access to healthcare. Here are the key points:
The WHO has prequalified a fourth HPV vaccine product, Cecolin®, for use in a single-dose schedule. This decision is based on new data that meets the criteria set out in the WHO’s 2022 recommendations for alternative, off-label use of HPV vaccines in single-dose schedules.
The addition of this HPV vaccine will help address the ongoing global supply challenges for HPV vaccines, which have been hampered by shortages since 2018. This will enable more girls to be vaccinated against cervical cancer, particularly in low- and middle-income countries.
The WHO aims to have 90% of girls fully vaccinated with the HPV vaccine by the age of 15 as part of its global strategy for cervical cancer elimination. The single-dose HPV vaccine is expected to facilitate achieving this target.
Cervical cancer is a preventable disease, with over 95% of the 660,000 annual cases globally caused by HPV. Every two minutes, a woman dies from cervical cancer, with 90% of these deaths occurring in low- and middle-income countries. The new SD-HPV Vac will help reduce these alarming statistics.
There has been significant funding committed towards the elimination of cervical cancer. This includes nearly US$ 600 million from various partners, such as the Bill & Melinda Gates Foundation (US$ 180 million), UNICEF (US$ 10 million), and the World Bank (US$ 400 million).
As of September 10, 2024, 57 countries are implementing the HPV vaccine schedule, up from 37 countries in 2023. The adoption of the SD-HPV Vac schedule has resulted in at least 6 million additional girls being reached with HPV vaccines in 2023.
The single-dose use indication for Cecolin® is included in the second edition of WHO’s technical document on considerations for HPV vaccine product choice. Public health advisory bodies can recommend “off-label” use of vaccines when supported by data and clear public health benefits, until manufacturers update their labels.
Overall, the introduction of the SD-HPV Vac marks a significant step forward in the global effort to eliminate cervical cancer, enhancing vaccine accessibility and addressing supply challenges effectively.
🌍 Today is World Diabetes Day! Managing diabetes effectively is key to a healthier life! Discover strategies for preoperative risk assessment, obesity management, and safe fasting during Ramadan. Let’s prioritise our health together! 💪
#SyenzaNews #WorldDiabetesDay #DiabetesManagement #RamadanFasting #ObesityManagement
🌍 How can self-collection methods improve cervical cancer screening?
A recent article from the National Cancer Institute explores the groundbreaking FDA approval for HPV tests that allow patients to safely collect their own vaginal samples in a healthcare setting. This innovation promises to enhance access to screening for underserved populations and could transform the future of cervical cancer prevention. Jump into the details and learn how this initiative is poised to address health disparities in the U.S.
#SyenzaNews #oncology #HealthcareInnovation #HealthTech #innovation
🌍 How can we combat the rising threat of Antimicrobial Resistance (AMR) in Africa?
The new guidance from Africa CDC presents a comprehensive framework for strengthening AMR surveillance. By implementing a One Health approach and enhancing collaboration, we can address the challenges posed by AMR and significantly improve public health outcomes across the continent.
Jump into the details of this critical initiative and discover how we can work together to forge a sustainable path forward!
#SyenzaNews #GlobalHealth #HealthcareInnovation #DataScience #AMR #OneHealth
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
